Clinical research is vital in order to improve the lives of our patients undergoing blood cell transplantation. The OSU BMT Program is involved in several National Institutes of Health (NIH) supported clinical trials designed to make transplants better tolerated and more successful overall. We are one of a select group of transplant centers involved in the NIH sponsored Blood and Marrow Transplant Clinical Trials Network (BMT CTN) and are also a main member of the National Cancer Institute (NCI) sponsored Cancer and Leukemia Group B (CALGB). We have access to the latest treatment developments in the field of blood and marrow transplantation.
Learn more about our clinical research and trials
Read our latest newsletter for open clinical trials within the BMT program.
Highlights of our accomplishments and current research:
- Spearheading efforts to find alternative therapies for patients with acute myeloid leukemia (AML). New research at the OSUCCC-James is helping determine which therapies improve chances for remission in the largest category of people with AML: those who have normal-looking chromosomes. Read more
- Received notable grants, including a five-year, $6.25 million allocation from the Leukemia & Lymphoma Society to develop new therapies and improve current therapies for chronic lymphocytic leukemia (CLL). The new grant funds four research projects and three clinical trials. The projects aim to develop and improve experimental drugs that block molecules needed by CLL cells to survive and grow.
- Earned a $9.8 million, five-year Program Project Grant (PPG) from the National Cancer Institute. In this study, scientists seek to understand how retroviruses can transform lymphocytes and cause blood cell proliferation that may lead to AML.
- Discovered a new tumor-suppressor gene and a unique chemical signature implicated in the development of human leukemia – findings that open opportunity and possibility for future study. The findings appeared in the March 2005 issue of the journal Nature Genetics.